Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100070, China
Location status: Recruiting
NCT Number: NCT06896994
To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Beijing, Beijing Municipality, 100070, China
Location status: Recruiting
The investigators aim to investigate whether or not esketamine combined with pregabalin and duloxetine to relieve pain in patients with PHN, and seek a rapid, effective and safe treatment for refractory patients with PHN
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In the esketamine group, in addition to receiving the combination of pregabalin and duloxetine, patients will also undergo a single intravenous infusion of esketamine.
Other names: pregabalin+duloxetine+esketamine
receiving the combination of pregabalin and duloxetine
Other names: pregabalin+duloxetine
Time frame: during 1 week
the mean of daily pain scores collected during week 1 of treatment measured using the Numerical Pain Rating Scale (NRS,, 0 represents no pain, and 10 represents the most severe pain.A higher score indicates more severe pain).
Time frame: 1 week, 2 weeks, 3 weeks, and 1 month after treatment
Averaged weekly NRS score of each participant.Generally, 0 represents no pain, and 10 represents the most severe pain.A higher score indicates more severe pain
Time frame: during the first week
percentages of patients having >50% reductions
Time frame: 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment
Quality of life (QoL) assessed by the SF-12 score (range 0-100, with higher scores indicating better health status).
Time frame: 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment
Sleep quality measured by PSQI score (range 0-21, with higher scores indicating poorer sleep quality).
Time frame: 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment
The proportion of patients with a response of "no change", "minimally improved", "much improved" or "very much improved" on PGIC.
Time frame: 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment
It consists of two sub-scales. Each sub-scale consists of 7 items and each item scored from 0 to 3. A higher score indicates more severe anxiety or depression. A score of 11 or above can indicate clinically significant anxiety or depression.
Time frame: 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 1 month after treatment
Averaged weekly consumption per analgesic of each participant
Time frame: 0 day, 1 day, 3 days, 7 days, 2 weeks,3 weeks, and 1 month after treatment
drug-related complications,such as dizziness, somnolence, gait disturbance, nausea, fatigue, diarrhea, dry mouth, mental symptom, etc
Contact information is provided by the study sponsor or research team.
Beijing Tiantan Hospital
Other
Intravenous Infusion of Esketamine in Combination With Pregabalin and Duloxetine for Postherpetic Neuralgia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07275762
Nervous System Diseases, Neuralgia
Nanjing, Jiangsu, China
View Trial DetailsNCT07361796
DNA Virus Infections, Herpes Zoster
Beijing, China
View Trial DetailsNCT07400640
DNA Virus Infections, Herpes Zoster
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07390279
Chronic Pain, Nervous System Diseases
Istanbul, Turkey (Türkiye)
View Trial Details